إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - ezetimibe - tablets - ezetimibe 10 mg - ezetimibe - primary hypercholesterolemia: ezecor administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezecor administered with a statin are indicated for use in patients with hofh.patients may also receive adjunctive treatments (e.g. ldl apheresis).homozygous sitosterolemia (phytosterolemia): ezecor are indicated for use in patients with homozygous familial sitosterolemia.

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - atomoxetine as hydrochloride - coated tablets - atomoxetine as hydrochloride 25 mg - atomoxetine - atomic is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. treatment must be initiated by a specialist in the treatment of adhd, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. diagnosis should be made according to current dsm criteria or the guidelines in icd. in adults, the presence of symptoms of adhd that were pre-existing in childhood should be confirmed. third-party corroboration is desirable and atomic should not be initiated when the verification of childhood adhd symptoms is uncertain. diagnosis cannot be made solely on the presence of one or more symptoms of adhd.based on clinical judgment, patients should have adhd of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - atomoxetine as hydrochloride - coated tablets - atomoxetine as hydrochloride 40 mg - atomoxetine - atomic is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. treatment must be initiated by a specialist in the treatment of adhd, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. diagnosis should be made according to current dsm criteria or the guidelines in icd. in adults, the presence of symptoms of adhd that were pre-existing in childhood should be confirmed. third-party corroboration is desirable and atomic should not be initiated when the verification of childhood adhd symptoms is uncertain. diagnosis cannot be made solely on the presence of one or more symptoms of adhd.based on clinical judgment, patients should have adhd of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - atomoxetine as hydrochloride - coated tablets - atomoxetine as hydrochloride 60 mg - atomoxetine - atomic is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. treatment must be initiated by a specialist in the treatment of adhd, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. diagnosis should be made according to current dsm criteria or the guidelines in icd. in adults, the presence of symptoms of adhd that were pre-existing in childhood should be confirmed. third-party corroboration is desirable and atomic should not be initiated when the verification of childhood adhd symptoms is uncertain. diagnosis cannot be made solely on the presence of one or more symptoms of adhd.based on clinical judgment, patients should have adhd of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - amlodipine as maleate - tablets - amlodipine as maleate 10 mg - amlodipine - mild to moderate hypertension. vasospastic angina (prinzmetal's or variant angina). chronic stable angina.

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - amlodipine as maleate - tablets - amlodipine as maleate 5 mg - amlodipine - mild to moderate hypertension. vasospastic angina (prinzmetal's or variant angina). chronic stable angina.

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - escitalopram as oxalate - tablets - escitalopram as oxalate 10 mg - escitalopram - treatment of depression and panic disorder. treatment of generalized anxiety disorder (gad), treatment of social anxiety disorder (social phobia).treatment of obsessive compulsive disorder.

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - escitalopram as oxalate - tablets - escitalopram as oxalate 20 mg - escitalopram - treatment of depression and panic disorder. treatment of generalized anxiety disorder (gad), treatment of social anxiety disorder (social phobia).treatment of obsessive compulsive disorder.

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - aripiprazole - tablets - aripiprazole 10 mg - aripiprazole - ariply is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.ariply is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (mdd). efficacy was established in two 6-week trials in adults with mdd who had an inadequate response to antidepressant therapy during the current episode.ariply is indicated for the treatment of irritability associated with autistic disorder. efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).

إسرائيل - الإنجليزية - Ministry of Health

unipharm ltd, israel - aripiprazole - tablets - aripiprazole 15 mg - aripiprazole - ariply is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.ariply is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (mdd). efficacy was established in two 6-week trials in adults with mdd who had an inadequate response to antidepressant therapy during the current episode.ariply is indicated for the treatment of irritability associated with autistic disorder. efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).